46 results about "Tumor tissue sample" patented technology

The invention discloses a preparation method and application of a colloidal gold immunochromatography test strip for detecting IDH1 mutant protein, and belongs to the field of rapid immunodetection. The colloidal gold chromatography test strip comprises a bottom plate, a sample pad, a nitrocellulose membrane, a water absorption pad and colloidal gold, the nitrocellulose membrane is sequentially provided with a detection line T and a quality control line C in the flowing direction of a sample, the detection line T is coated with IDH1 mutant protein, and the quality control line C is coated with a second antibody corresponding to a monoclonal antibody of the IDH1 mutant protein. Clinical tumor tissue samples collected in real time in glioma resection surgery are treated, an object to be detected and an immune gold label are mixed, incubated and dropped in a test strip sample adding hole, and the object to be detected runs along the test strip under the driving of a buffer solution and generates visual color change. The test strip has the advantages of being rapid in reaction, easy and convenient to operate, convenient to carry, high in specificity and the like, makes up the blank of an IDH1 mutant protein concentration quantitative method, and has good clinical application value.

Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.

This invention discloses a breast cancer classification method based on Piezo1 expression. After obtaining tumor tissue samples from patients, the method detects the Piezo1 protein expression level using immunohistochemistry and classifies them into high-expression and low-expression types according to a validated scoring standard. This classification result guides individualized treatment, with high-expression patients recommended for treatment regimens including inhibitors of mechanotransmission pathways. By integrating tumor mechanotransmission characteristics into the clinical classification system, this invention can identify a subgroup of breast cancer driven by an abnormal mechanotransmission microenvironment that cannot be distinguished by traditional molecular classification. This not only improves and supplements the existing classification framework, making the understanding of breast cancer heterogeneity more comprehensive, but also more accurately predicts the invasiveness, metastasis potential, and poor prognostic risk of these patients.

The invention discloses a method for predicting the curative effect of triple negative breast cancer immunotherapy by spatially quantizing CD39 + CD103 + CD8 + T cells, and relates to the technical field of biology.The method comprises the following specific steps that S1, an FFPE tumor tissue sample of a TNBC subject before immunotherapy is obtained, and a continuous section with the thickness of 3-5 microns is prepared and attached to a positive charge glass slide; s2, staining the section by using a combination containing CD8 / CD103 / CD39 / Pan-CK antibodies through a TSA sequential staining method, and then re-staining cell nucleuses by using DAPI; according to the method, spatial quantitative analysis is performed on a specific CD39 + CD103 + CD8 + T cell subset, a percentage index of target cells in CD8 + T cells and an average distance index of the target cells and nearest Pan-CK positive cells in a cancer nest region are set, and the target cells are determined according to comparison between the two indexes and a preset threshold value. According to the method, whether a subject is a potential benefit crowd treated by an anti-PD-1 / PD-L1 immune checkpoint inhibitor or not is accurately judged, a standardized technical means is provided for clinically screening the potential benefit crowd for immunotherapy, the accuracy and effectiveness of triple-negative breast cancer immunotherapy are effectively improved, and invalid treatment is reduced.

The invention relates to the technical field of tumor sample detection, in particular to a tumor tissue sample detection device which comprises a scanner body, the scanner body comprises a detection table, a [-shaped base is fixedly embedded into the bottom of the detection table, and a bearing mechanism is fixed to the top of the base. The bearing mechanism comprises a first carrying plate and a second carrying plate which are both fixedly connected with the base, two sliding rails are fixed to the top face of the base, electric sliding blocks are connected to the sliding rails in a sliding mode, and a clamping mechanism is arranged at the tops of the electric sliding blocks. According to the device, the first notches of the arc-shaped plates are clamped to the glass slides, the inner sides of the arc-shaped plates can clamp the detection vessels at the same time, and the two arc-shaped plates are used for clamping and conveying the detection vessels and the glass slides at the same time for detection and standby application; the two arc-shaped plates are used for independently clamping and conveying the glass slide for detection and standby application, and the detection vessel and the glass slide can be conveniently conveyed at the same time according to user needs for sample detection.

A method for obtaining a corrected value for the diffusion coefficient of nanoparticles can be used to assist in the development of tumor drugs. The method disclosed herein includes the following steps: collecting tumor tissue samples; reconstructing the internal morphology of the samples using electron microscopy or nuclear magnetic resonance to obtain the three-dimensional structure of the samples; and analyzing and statistically analyzing the three-dimensional structure of the samples to obtain the porosity ε of the tumor tissue and the average diameter r of the tumor tissue cytoplasmic matrix fibers. f The average diameter r of nanoparticles within the cytoplasm of tumor tissue cells was obtained using a particle size analysis device. s A predictive model for the diffusion coefficient of nanoparticles was constructed, taking into account the porosity ε of the tumor tissue and the average diameter r of the tumor tissue cytoplasmic matrix fibers. f and the average diameter r of nanoparticles s Substitute the values ​​into the prediction model to obtain the predicted value of the diffusion coefficient of the nanoparticles; then correct the predicted value of the diffusion coefficient of the nanoparticles to obtain the corrected value of the diffusion coefficient of the nanoparticles.

There is provided a method for quantifying texture features in histological sample from a tumor sample, comprising:receiving a digital image of the histological sample, thendividing the digital image into a plurality of sub-areas, thenusing a trained machine learning model to predict a presence of at least one biological feature for each of the sub-areas, where a probability for the presence of the biological feature is represented by a value, thenforming a data matrix by arranging the values for the probabilities of the biological features in the same way as the sub-areas are arranged in relation to the digital image, thenapplying image analysis to the data matrix for a set of texture features, to produce a quantification of at least one texture feature.

The invention discloses a digestive tract tumor biopsy sampling device convenient for puncture and sampling for medical oncology, which relates to the technical field of tumor biopsy sampling and comprises a biopsy device, a limiting seat and a base. According to the alimentary canal tumor biopsy sampling device convenient to puncture and sample for the medical oncology, tumor tissue can be accurately contained through the sampling groove, fragmentation of a tumor tissue sample is avoided, it is guaranteed that the tissue sample meets the tissue form needed by detection, the sample quality is guaranteed, the outer sleeve needle covers the sampling groove after sampling, the sample can be fixed and cannot fall off, and the sampling efficiency is improved. The tissue is prevented from remaining in the body or being polluted during withdrawing, and meanwhile the risks of bleeding and tissue damage in the puncture process are reduced; enough samples can be obtained through one-time operation, the repeated puncture frequency is reduced, the operation time is shortened, the pain of a patient is relieved, and the operation efficiency is improved; and the modularized puncture needle design allows medical staff to quickly adjust the puncture depth according to individual differences, and the flexibility is high.

The application provides a solid tumor targeting index detection method and a reagent combination thereof, including detection of a solid tumor targeting therapy molecular marker and detection of a solid tumor microenvironment, and the evaluation method comprises the following steps: collecting a fresh tumor tissue sample; preparing a tumor tissue sample to be detected into a single cell suspension; establishing a flow cytometry on-machine model; detecting the solid tumor targeting therapy molecular marker by using flow cytometry; and detecting the solid tumor microenvironment by using flow cytometry. The application has the advantages of less required samples, short detection time, and the ability to provide information about various factors that are helpful for prognosis and treatment, including quantification of tumor infiltrating lymphocytes, the proportion of tumor cells with positive expression of PD-L1, EGFR and ALK, and the proportion of tumor cells with co-expression.

The invention discloses a PARP inhibitor sensitivity prediction method based on a specific cell cluster and application. The method comprises the following steps: acquiring an ovarian cancer tumor tissue sample of a subject; detecting whether a specific cell cluster exists in the sample or not, and determining the abundance of the specific cell cluster, wherein the specific cell cluster comprises an IFN epithelial cell cluster CN12 taking an IFN tumor cell as a center and / or a TAM enrichment cluster CN29 taking an M2 type tumor related macrophage as a center; according to the detection result, predicting according to at least one of the following rules: if the CN12 abundance before treatment is greater than 0.8%, the CN29 abundance before treatment is greater than 32.7%, the CN12 abundance after treatment is greater than 0.009%, the CN29 abundance after treatment is greater than 2.9%, or the SPP1 cell density before treatment is greater than 1.7%, predicting that the drug resistance is not sensitive or easily generated. The prediction model is established from a cell cluster space tissue level, and the method has the advantages of high prediction accuracy, flexible sample requirements, high operability and the like.

The utility model discloses a gynecological tumor sampler which comprises a guide mechanism and a sampling mechanism, the sampling mechanism comprises a sampling framework and a sampling air bag sleeved outside the sampling framework, and threads are arranged on the sampling air bag; the guide mechanism comprises a guide framework, a guide head and an expansion air bag, the guide head is fixedly connected to the other end of the guide framework, the guide framework is connected to the top of the sampling framework through a first connecting structure, and the expansion air bag sleeves the guide framework and is located between the guide head and the first connecting structure; in the full state, the maximum outer diameter of the expansion air bag is not smaller than the maximum outer diameter of the sampling air bag. Through the matching of the expansion air bag and the sampling air bag, different patients can be adapted, and after an expected position is reached, the sampling air bag is inflated, so that a thread is propped against the surface of a tumor tissue, and scratching is started to obtain a tumor tissue sample; meanwhile, after sampling is finished, the air bags can be taken out of the body of the patient more conveniently and easily by reducing the sizes of the air bags.

The invention relates to the technical field of medical image analysis and molecular diagnosis. The invention discloses a multi-mode prognosis evaluation method for local advanced cervical cancer. The method comprises the following steps: acquiring a magnetic resonance T2 weighted image and a tumor tissue sample of the same patient before treatment; based on the magnetic resonance T2 weighted image, a first risk score is output through a deep learning prognosis prediction model, and first risk layering is completed; screening prognosis related key protein combinations based on proteomics expression data of tumor tissue samples to complete second risk stratification or clustering typing; and fusing the first risk layering result and the second risk layering / clustering typing result to generate a comprehensive multi-mode prognostic risk assessment report. According to the method, the MRI image and the proteomics data are fused through the full-automatic deep learning model, non-invasive prognosis evaluation of cervical cancer is realized, high-risk / low-risk patients can be accurately distinguished without manual sketching, individualized treatment decision is supported, and the clinical transformation value is remarkably improved.

The present invention belongs to the technical field of immune cell culture, and specifically relates to a composition and kit for expanding tumor infiltrating lymphocytes, and an expansion method therefor. Provided is a composition for expanding tumor infiltrating lymphocytes for a trace amount of tumor tissue, i.e., a tumor biopsy sample, to perform the expansion of tumor infiltrating lymphocytes, which solves the problem that a large amount of a tumor tissue sample is required for tumor infiltrating lymphocytes, and is suitable for patients who cannot undergo surgical resection to obtain tumor tissue. In addition, by means of optimizing the combination and working concentration of antibody stimulants, a process flow for expanding tumor infiltrating lymphocytes on the basis of biopsy samples is established, such that the stemness of the expanded tumor infiltrating lymphocytes is maintained, and the killing ability is improved, thereby ensuring the anti-tumor efficacy after reinfusion into the body.

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

The invention relates to the technical field of medical data communication, in particular to a tumor treatment path dynamic optimization method and system, and the method comprises the steps: collecting a tumor tissue sample, and obtaining an integrated molecular spectrum of a tumor patient; performing multi-modal decision analysis on the integrated molecular spectrum to generate a multi-dimensional treatment strategy including a targeted treatment decision and an immunotherapy decision; constructing an individualized treatment path comprising a current treatment node and at least one future evolution node according to the multi-dimensional treatment strategy; physiological change data of the tumor patient is continuously monitored, and the continuity weight of each future evolution node is calculated based on the physiological change data; and sequencing the future evolution nodes according to the continuity weight and generating a new individualized treatment path based on the current treatment node. According to the invention, the core problem that the existing tumor treatment scheme cannot respond to the dynamic evolution of the tumor in real time due to static single detection is effectively solved, and the self-adaptive optimization of the treatment path along with the disease progress is realized.

The invention relates to the technical field of biomedical engineering, and discloses a human-derived premature colorectal tumor organoid and a culture method and application thereof, and the culture method comprises the following steps: obtaining a fresh tumor tissue sample of a premature colorectal cancer patient of which the onset age is less than 50 years old; digesting the pretreated tissue blocks for 30 to 60 minutes by using digestive juice containing type IV collagenase; mixing the digested cell suspension and matrigel according to a volume ratio of 1: 1 to 1: 1.5; embedding the mixture into a culture plate, and adding a colorectal tumor organoid culture medium for culture after gel formation. Aiming at the special biological characteristics of the early-onset colorectal cancer tissue, a differentiated digestion strategy of combination of type IV collagenase and DNase I is adopted, so that the organoid formation rate is remarkably improved, the cultured organoid keeps high molecular consistency with the primary tumor, stable passage can be realized, and the culture cost is reduced. And a reliable in-vitro model platform is provided for mechanism research and drug screening of the premature colorectal cancer.

The invention provides a tongue squamous cell carcinoma assessment method based on targeted sequencing and clinical characteristic parameters, and relates to the technical field of tongue squamous cell carcinoma assessment computer processing programs, the method comprises the following steps: S01, obtaining a tumor tissue sample of a tongue squamous cell carcinoma patient, and detecting gene mutation data through a targeted sequencing technology; s02, screening mutant genes significantly related to clinical pathological characteristics of the patient to obtain first N genes with the highest mutation frequency; s03, constructing a prognosis risk scoring model, converting the first N genes with the highest mutation frequency into a binary mutation state, then taking the binary mutation state as a variable, analyzing the training model through multivariable Cox proportional risk regression, and calculating the risk score of the patient; and S04, judging a principle according to a risk median. According to the invention, an individualized risk assessment tool is provided for clinic, and a doctor is assisted to formulate a more reasonable treatment and follow-up visit scheme, so that the prognosis and survival outcome of a patient are effectively improved.

The invention relates to the field of biological medicine, in particular to a lactic dehydrogenase LDHB protein 196-site serine phosphorylation antibody as well as a preparation method and application thereof. On the basis of the 196-site serine phosphorylated polypeptide of the lactic dehydrogenase LDHB protein, the 196-site serine phosphorylated antigen and antibody of the lactic dehydrogenase LDHB protein are prepared, and a preparation method of the 196-site serine phosphorylated antibody of the lactic dehydrogenase LDHB protein is provided. The prepared lactic dehydrogenase LDHB protein 196-site serine phosphorylated antibody can be used for detecting low-abundance LDHB Ser196 signals, is suitable for various detection platforms such as Western blot and immunohistochemistry, and meets the detection requirements of tumor tissue samples.

A clinical decision support system and method for predicting a clinical response of a target tumor to an immune checkpoint blocking therapy (ICB) by: obtaining a training dataset, the training dataset comprising training transcriptome records of tumor tissue samples of a plurality of known responders and a plurality of known non-responders to the ICB; deconvolution is carried out on the training data set to identify differential expression genes DEG in the training data set, the DEG is regarded as features of the training data set, and related responder and non-responder states are regarded as labels recorded in the training data set; performing regression analysis on the features to select a feature subset which can predict the responder tag or the non-responder tag and related feature weights; incorporating the feature subset and the associated feature weight into a reaction estimation model; receiving transcriptome data of the target tumor tissue sample; the transcriptome data is processed using the generated response estimation model to generate an estimated response indicator indicative of a possible response of the target tumor to the ICB.

w The invention discloses a detection method for predicting efficacy and prognosis of immunotherapy for small cell lung cancer based on ATAD2 expression, and relates to the technical fields of molecular biology and cancer treatment. The method comprises the following steps: extracting a tumor tissue sample of a small cell lung cancer patient through surgical resection; Detecting the tumor tissue sample to obtain ATAD2 expression level, wherein the detection adopts an immunohistochemical staining method. According to the invention, the expression level of ATAD2 in tumor tissues of small cell lung cancer is quantitatively evaluated by immunohistochemical detection technology, and the molecular marker information is systematically correlated with the clinical and pathological characteristics of patients by combining Cox regression analysis and Logistic regression analysis, so that the comprehensive prediction of immunotherapy efficacy and patient survival time is realized.

The application discloses a postoperative care scheme optimization method and an intelligent chip for liver cancer, and relates to the technical field of postoperative care for liver cancer. The method comprises the following steps: performing multidimensional detection on a liver cancer tumor tissue sample of a target user to obtain a multidimensional detection data set, determining a tumor immune microenvironment type, and generating an initial postoperative care scheme; obtaining a predicted recurrence and metastasis risk probability of the target user within a preset rehabilitation period; evaluating the initial postoperative care scheme based on baseline state detection information of the target user to generate a care scheme strength and a baseline state score; formulating an adaptive rehabilitation intervention rhythm and an adaptive risk monitoring mechanism according to the predicted recurrence and metastasis risk probability, the care scheme strength and the baseline state score; and performing care on the target user according to the initial postoperative care scheme and dynamically optimizing the postoperative care scheme according to the adaptive rehabilitation intervention rhythm and the adaptive risk monitoring mechanism. The application realizes individualized and accurate adaptation of the postoperative care scheme for liver cancer.

The invention belongs to the technical field of immune cell culture, and particularly relates to a tumor infiltration lymphocyte amplification composition, a kit and an amplification method thereof. The invention provides the tumor infiltration lymphocyte amplification composition aiming at a trace amount of tumor tissue, namely a tumor puncture sample, the tumor infiltration lymphocyte amplification composition is used for amplifying the tumor infiltration lymphocyte, the problem that the tumor tissue sample size required by the tumor infiltration lymphocyte is large is solved, and the tumor infiltration lymphocyte amplification composition is suitable for a patient who cannot receive the tumor tissue obtained by surgical excision. Besides, by optimizing the antibody stimulant combination and the working concentration and establishing the technological process for amplifying the tumor infiltration lymphocytes based on the puncture sample, the dryness of the tumor infiltration lymphocytes obtained through amplification is maintained, the lethality is improved, and therefore the anti-tumor curative effect after the tumor infiltration lymphocytes are infused back into the body is guaranteed.

The invention relates to a brain tumor tissue sample slicing device. The brain tumor tissue sample slicing device comprises a machine shell, a lifting rack is arranged on the machine shell, a clamping piece is arranged on the lifting rack, a tool bit is further arranged on the machine shell, a sliding seat is arranged on the machine shell, the sliding seat is in sliding connection with the machine shell, and a first linkage part is arranged between the sliding seat and the lifting rack; a plurality of supporting shafts and a conveying belt are arranged on the side, away from the tissue block, of the tool bit, the supporting shafts are rotationally connected with the sliding base, and second linkage parts are arranged between the supporting shafts and the lifting rack. By means of the first linkage part, the horizontal distance between the tool bit and the tissue can be automatically compensated in cooperation with the sliding seat during slicing each time in the slicing process, and the phenomenon that the thicknesses of follow-up tissue slices are not uniform due to gradual consumption of samples is reduced; the second linkage part is matched with the conveying belt to automatically convey and move away the tissue pieces which are cut off and fall onto the conveying belt during slicing each time in the slicing process, and sample damage, adhesion and operation interruption caused by accumulation of the tissue pieces at the tool bit are reduced.

Methods of treating a tumor by collecting a baseline blood sample, administering anti-IL-27 antibodies, and antigen-binding portions thereof, collecting a post-dose blood sample, measuring a score for one or more biomarkers in each of the baseline and post-dose blood samples, and treating the subject with the anti-IL-27 antibodies, or antigen-binding portions thereof, alone or in combination with toripalimab are disclosed. The disclosure also relates to methods for selecting a subject having a tumor for treatment with anti-IL-27 antibodies and methods for treating a subject having a tumor by obtaining a tumor tissue sample from the subject, determining a percentage of tumor tissue sample area that is IL-27+ or PD-L1+ using IHC, and selecting the subject for treatment with the anti-IL-27 antibodies or administering the anti-IL-27 antibodies or antigen-binding portion thereof, if the percentage of tumor tissue sample area that is IL-27+ is at least about 1%, or if the percentage of tumor tissue sample area that is PD-L1+ is less than about 50%.

This patent discloses a method for detecting a patient's tumor burden. DNA is extracted from a patient's tumor tissue sample, a predetermined number of biomarker genes are selected to form a biomarker gene cluster ("customized gene cluster"). A DNA sample of circulating free cells in the patient's body fluid is isolated. DNA sequences containing biomarker genes are enriched in the free DNA fragments. The enriched DNA is sequenced. The mutant and normal DNA sequences in the enriched DNA are counted. The patient's tumor burden is then determined. Preferably, mutations in therapeutically relevant genes ("drug-targeted genes") are detected simultaneously with the detection of the customized gene cluster.

The invention discloses a tumor neoantigen prediction method and system based on full-length transcriptome sequencing, electronic equipment and a storage medium, and the method comprises the following steps: carrying out full-length transcriptome sequencing on a tumor tissue and a normal control tissue, and carrying out transcription annotation to obtain a tumor specific transcript set; performing single base resolution analysis on the tumor specific transcript, and identifying mutation information of tumor cells; a false positive event is eliminated, and a tumor specific abnormal transcript with a potential protein coding function is identified in combination with open reading frame prediction; performing cross integration on the mutation information and the identification result of the abnormal transcript, extracting a complete amino acid sequence coded by the abnormal transcript, and constructing a candidate new antigen polypeptide library; identifying the HLA type of the tumor tissue sample; and screening the tumor neoantigen from the candidate neoantigen polypeptide library in combination with an HLA typing result. According to the invention, the tumor specific neoantigen generated by abnormal splicing, gene fusion and other atypical transcription events can be accurately identified.

Provided are a method and system for determining a methylation level of a target CpG site of a tumor tissue, a computer device, and a medium. The method comprises: acquiring a first methylation measurement result of a mixed tumor tissue sample and a second methylation measurement result of a paired paracancerous tissue sample, wherein the mixed tumor tissue sample comprises a tumor tissue and a paracancerous tissue; on the basis of the first methylation measurement result and a third methylation measurement result of a reference paracancerous tissue sample, determining a distribution of a read, in the mixed tumor tissue sample, that comprises a target CpG site and derives from the tumor tissue or the paracancerous tissue; and on the basis of the determined distribution, the first methylation measurement result, and the second methylation measurement result, determining a methylation level of the target CpG site of the tumor tissue in the mixed tumor tissue sample.

The present invention discloses a biomarker for the detection of bile duct cancer and its application. The biomarker combination for the detection of bile duct cancer of the present invention includes a DNA+RNA dual-level detection of tumor tissue samples, detecting a wide range of genetic variations, including single nucleotide variations (SNVs), insertions and deletions (indels), copy number variations (CNVs), gene fusions (Fusion) and microsatellite instability (MSI), with more comprehensive detection; at the same time, the biomarker combination also includes a site combination for identifying potential sample contamination or contamination, which can achieve matching and proofreading of DNA+RNA samples, making the detection more accurate; the biomarker combination of the present invention can be used for the diagnosis, treatment, prognosis and other stages of the occurrence and development of bile duct cancer, laying the foundation for comprehensive and systematic detection and research of bile duct cancer.

This invention discloses the application of BHLHE40 in the preparation of prognostic assessment kits and therapeutic drugs for retinoblastoma. Through a series of in vitro and in vivo experiments, this invention demonstrates that knocking down BHLHE40 expression significantly inhibits the proliferation of retinoblastoma cells, exhibiting a significant tumor-suppressive effect. Therefore, it is proposed that BHLHE40 inhibitors can be used in the preparation of therapeutic drugs for retinoblastoma, providing a new, effective, and safe treatment option for RB patients. Furthermore, BHLHE40 can serve as a drug target to guide subsequent drug development. In addition, this invention also utilizes clinical tumor tissue samples to demonstrate that high BHLHE40 expression is significantly positively correlated with high-risk pathological features such as optic nerve invasion, scleral invasion, and choroidal invasion, suggesting that BHLHE40 can serve as an effective biomarker for predicting high-risk pathological features, assisting physicians in treatment decisions.

The invention relates to the technical field of pathological detection of tumor tissue samples, and provides a storage, analysis and detection device for thoracic surgery tumor tissue samples. Comprising a sealing shell, a tray module, a digital pathological scanner, a sample storage vessel, a lifting transfer module, a static sealing assembly, a sample angle adjusting module, a circulating refrigeration module and an inert gas circulating conveying module, through the design of integrating a sealing environment, mechanical linkage sealing control, multifunctional lifting transfer, integrated sample adjustment and full-process automation, full-process inert gas protection, automatic transfer with zero manual contact, accurate multi-angle detection and partitioned environment isolation are realized through multiple innovative designs. The problems of large occupied area, low detection efficiency, insufficient sealing and repeated manual operation of split design in the prior art are solved, and the device has the characteristics of preventing sample oxidation, keeping sample activity and improving detection precision and efficiency.